Loading...
•
Jun 30, 2022
STERIS Q1 2023 Earnings Report
STERIS's financial performance for Q1 2023 reflected solid revenue growth and strong demand despite supply chain challenges.
Key Takeaways
STERIS announced a 19% increase in revenue, reaching $1.2 billion. Constant currency organic revenue grew by 6%. The company reported an EPS of $1.10 and an adjusted EPS of $1.90.
Revenue increased by 19% as reported, with a 6% constant currency organic growth.
Reported EPS was $1.10, while adjusted EPS reached $1.90.
Healthcare revenue grew by 16% to $698.5 million.
Free cash flow increased to $117.1 million.
STERIS
STERIS
STERIS Revenue by Segment
STERIS Revenue by Geographic Location
Revenue by Segment
AST Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comRevenue by Geographic Location
Ireland Revenue
CapyFin.comUnited States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For fiscal year 2023, STERIS anticipates constant currency organic revenue growth of approximately 10%. As reported revenue is expected to increase approximately 9%. Adjusted earnings per diluted share are now anticipated to be in the range of $8.40 to $8.60.
Positive Outlook
- Constant currency organic revenue growth is anticipated to be approximately 10%.
- As reported revenue is expected to increase approximately 9%.
- Adjusted earnings per diluted share are anticipated to be in the range of $8.40 to $8.60.
- Demand for our products remains strong.
- Significant backlog in Healthcare capital equipment.
Challenges Ahead
- Ongoing supply chain challenges.
- Procedure volumes somewhat lighter than anticipated.
- Approximately $100 million in anticipated negative impact of foreign currency fluctuations on as reported revenue.
- Approximately $0.10 of adverse impact from foreign currency fluctuations on adjusted earnings per diluted share.
- Slightly lower revenue outlook.
Revenue & Expenses
Visualization of income flow from segment revenue to net income